The most dangerous health threats are the ones you cannot see. In Helsinki, a startup has spent the last six years building a map for one of them, charting the invisible spread of antibiotic resistance through the world’s wastewater, soil, and rivers. Resistomap sells a service that starts with a sample jar and ends with a dashboard, translating genetic sludge into a readable warning system for public health officials, water utilities, and food producers [Resistomap homepage, retrieved 2024].
A service built on a SmartChip
The company’s wedge is a complete laboratory and data analysis package. Clients send in environmental samples [LinkedIn, retrieved 2024]. Resistomap’s lab then uses a high-throughput qPCR system from Takara Bio called a SmartChip to test for hundreds of antibiotic resistance genes (ARGs) at once, moving from DNA extraction to interpreted results [Dealroom, retrieved 2024]. The final deliverable is access to the Resistomap Platform, a secure cloud environment where customers can explore and report on their antimicrobial resistance (AMR) data [Resistomap Technology, retrieved 2024].
The team and the tailwind
Resistomap was launched in 2018 by microbiologist Dr. Windi Muziasari and William Nurmi [Resistomap About us, retrieved 2024]. Muziasari, the CEO, built her expertise monitoring AMR in environmental samples during her PhD and postdoc at the University of Helsinki, and she has become a frequent voice on the global stage [Terrapinn, retrieved 2026] [YouTube, retrieved 2026]. The market tailwind is the growing, urgent recognition of AMR as a silent pandemic. Resistomap’s focus on environmental monitoring places it in a less crowded niche with a potentially wider early-warning net. Their recent development of a dedicated Water Biosecurity Platform signals a push to productize for a key industrial customer segment [Resistomap Water Biosecurity Platform, retrieved 2026].
Traction and the competitive map
In November 2023, the company secured a €2 million seed round led by impact investor Ananda Impact Ventures, with participation from Gaingels [EU-Startups, Nov 2023].
| Company | Focus | Key Differentiator |
|---|---|---|
| Resistomap | Environmental AMR surveillance | End-to-end service from sampling to cloud-based data platform |
| C.E.C Analytics | Hospital wastewater monitoring | Focus on healthcare facility effluents as a specific point source |
The scale and the skepticism
The ambition is to become the global biosurveillance network for antimicrobial resistance. The company must navigate several specific challenges:
- Sales motion: Converting pilot projects into recurring contracts with large utilities or national health agencies.
- Interpretation burden: Building analytical tools that clearly answer the "so what?" for a water plant manager.
- Geographic expansion: Building a reliable global sampling network.
The company’s real competition is the entrenched incumbent of doing nothing. Its task is to prove that the cost of its map is far lower than the cost of navigating the next pandemic blind.